{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:02:11Z","timestamp":1782536531633,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejphar.2017.07.026","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T01:45:13Z","timestamp":1500083113000},"page":"147-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi"],"prefix":"10.1016","volume":"812","author":[{"given":"Luigino","family":"Calzetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erino","family":"Rendina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.07.026_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0034-5687(01)00252-3","article-title":"High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects","volume":"127","author":"Binks","year":"2001","journal-title":"Respir. Physiol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2015.03.007","article-title":"Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3\/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways","volume":"32","author":"Calzetta","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2015.03.023","article-title":"Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi","volume":"131","author":"Calzetta","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2017.07.026_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejphar.2015.09.007","article-title":"Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia","volume":"765","author":"Calzetta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.113.204644","article-title":"Effect of the mixed phosphodiesterase 3\/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone","volume":"346","author":"Calzetta","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib7","article-title":"Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi","author":"Calzetta","year":"2017","journal-title":"Accepted"},{"key":"10.1016\/j.ejphar.2017.07.026_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0043-2016","article-title":"LABA\/LAMA combination in COPD: a meta-analysis on the duration of treatment","volume":"26","author":"Calzetta","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejphar.2017.07.026_bib9","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1165\/rcmb.2011-0056OC","article-title":"Pharmacological characterization of adenosine receptors on isolated human bronchi","volume":"45","author":"Calzetta","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pupt.2015.02.007","article-title":"Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD","volume":"31","author":"Cazzola","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib11","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2015.08.005","article-title":"Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside","volume":"109","author":"Cazzola","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2017.07.026_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/15412555.2014.922172","article-title":"Translational study searching for synergy between glycopyrronium and indacaterol","volume":"12","author":"Cazzola","year":"2015","journal-title":"COPD"},{"key":"10.1016\/j.ejphar.2017.07.026_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-016-0500-y","article-title":"Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation","author":"Cazzola","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2017.07.026_bib14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1165\/rcmb.2010-0306OC","article-title":"Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi","volume":"45","author":"Cazzola","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2014.10.025","article-title":"Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi","volume":"745","author":"Cazzola","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12931-016-0386-8","article-title":"Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells","volume":"17","author":"Cazzola","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2017.07.026_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1378\/chest.13-1579","article-title":"Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study","volume":"145","author":"Celli","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2017.07.026_bib18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2017.07.026_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2017.07.026_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12931-015-0181-y","article-title":"Understanding the contribution of native tracheobronchial structure to lung function: CT assessment of airway morphology in never smokers","volume":"16","author":"Diaz","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2017.07.026_bib21","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2017.07.026_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-15-78","article-title":"Safety and tolerability of once-daily umeclidinium\/vilanterol 125\/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study","volume":"15","author":"Donohue","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2017.07.026_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rmed.2016.01.001","article-title":"Magnitude of umeclidinium\/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials","volume":"112","author":"Donohue","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2017.07.026_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bjp.0701897","article-title":"Influence of receptor reserve on \u03b2\u2010adrenoceptor\u2010mediated responses in human lung mast cells","volume":"124","author":"Drury","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib25","unstructured":"GOLD, 2017. Global initiative for chronic obstructive lung disease. Global Strategy for Diagnosis, Management, and Prevention of COPD \u2013 2017. Available at: \u3008http:\/\/goldcopd.org\/gold-2017-global-strategy-diagnosis-management-prevention-copd\/\u3009. (Accessed 9 March 2017)."},{"key":"10.1016\/j.ejphar.2017.07.026_bib26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1378\/chest.12-1766","article-title":"Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging","volume":"143","author":"Hogg","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2017.07.026_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.pupt.2012.12.001","article-title":"Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD","volume":"26","author":"Kempsford","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib28","first-page":"7","article-title":"Dysfunctional lung anatomy and small airways degeneration in COPD","volume":"8","author":"Martin","year":"2013","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.ejphar.2017.07.026_bib29","series-title":"Fitting Models to Biological Data Using Linear and Nonlinear Regression: a Practical Guide to Curve Fitting","author":"Motulsky","year":"2004"},{"key":"10.1016\/j.ejphar.2017.07.026_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2017.01.006","article-title":"Optimizing drug delivery in COPD: the role of inhaler devices","volume":"124","author":"Rogliani","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejphar.2017.07.026_bib31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejphar.2015.04.042","article-title":"Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi","volume":"761","author":"Rogliani","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.07.026_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pupt.2013.01.002","article-title":"The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle","volume":"26","author":"Rogliani","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.112.198481","article-title":"In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action","volume":"344","author":"Slack","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.07.026_bib35","unstructured":"US Food and Drug Administration, 2016. ANORO\u00ae ELLIPTA\u00ae safely and effectively. Reference ID: 3891924. Available at \u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203975s003lbl.pdf\u3009. (Accessed 28 February 2017)."},{"key":"10.1016\/j.ejphar.2017.07.026_bib36","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917304703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917304703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T09:50:24Z","timestamp":1569837024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917304703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":36,"alternative-id":["S0014299917304703"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.07.026","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}